GLP-1 Price Index
A documented, reproducible index of GLP-1 program costs, computed from verified and provider-reported pricing in our evidence ledger. Categories are kept separate so clinically or commercially different options are never merged into one misleading number.
Mixed-status snapshot: 1 first-party Verified price, 5 Provider Reported. This is a market snapshot, not yet a fully verified index. The Compounded Semaglutide Standard Injection snapshot sits at 100 (baseline = 100), with a current median effective monthly cost of $187.5 across 6 eligible programs (1 first-party Verified, 5 Provider Reported). Baseline is this first documented snapshot; month-over-month movement will appear once a second snapshot exists.
Current index value
| Provider | Effective monthly cost | Evidence status |
|---|---|---|
| OrderlyMeds | $74 | Provider Reported |
| NexLife | $119 | Verified (first-party) |
| Mochi Health | $178 | Provider Reported |
| Henry Meds | $197 | Provider Reported |
| Eden Health | $229 | Provider Reported |
| MEDVi | $299 | Provider Reported |
Median = $187.5. Index value = (current median ÷ baseline median) × 100 = 100. Median is used rather than mean; each eligible program is equally weighted; providers are never weighted by affiliate status, revenue, or traffic. Download: CSV · JSON.
How the index is calculated
Each index tracks one clearly defined category. We take every eligible program’s effective monthly cost — total mandatory payments for the treatment period divided by months supplied — and compute the category median. The baseline-period median is set to 100, and the current index value is the current median divided by the baseline median, times 100. Provider-reported figures are included but flagged; only first-party captures are labeled Verified. Programs with conflicting or missing pricing are excluded, not assigned a favorable default. Full method: price-index methodology.
How to read the index value
The index value is a single number that expresses where current prices sit relative to the baseline period. A value of 100 means the category median matches the baseline exactly. A value of 110 means the median has risen 10 percent since baseline; 90 means it has fallen 10 percent. Because this is the first documented snapshot, the value is 100 by definition, and no movement can be shown until a second snapshot is captured under the same methodology version.
The index deliberately uses the median rather than the average, because a single very cheap or very expensive program would distort an average and misrepresent what a typical patient pays. It also weights every eligible program equally rather than by size, traffic, or any commercial relationship, so a large advertiser cannot pull the index toward its own pricing. Programs with conflicting evidence, undisclosed mandatory fees, or introductory-only pricing are excluded from the median rather than assigned a favorable placeholder, which keeps the number honest even when it means a smaller sample.
Why categories are never merged
There is no single "GLP-1 price" on this site, and that is intentional. Compounded semaglutide, compounded tirzepatide, sublingual ODT, microdose programs, and brand medications occupy different clinical and commercial categories with different cost structures. Averaging a $145 compounded semaglutide program with a $1,086 brand tirzepatide list price would produce a number that describes no real patient's decision. Each category therefore carries its own index, its own baseline, and its own sample, and the site refuses to publish a blended figure that would mislead more than it informs.
Limitations
This first snapshot sets the baseline, so the index reads 100 by definition and no month-over-month change is available yet. Five of six programs are Provider Reported rather than first-party Verified, which lowers confidence; as first-party captures are completed the sample will strengthen. The index covers only compounded semaglutide standard injection at the lowest available plan — microdose, sublingual ODT, tirzepatide, and brand categories are tracked as separate indexes and must never be merged with this one.
Sources
- Evidence ledger: evidence-ledger.csv
- Price-index dataset: price-index.json
- Provider pricing captured from provider sites and major publishers (Forbes Health, U.S. News), July 2026.
- FDA — compounded GLP-1 status and 2025–2026 shortage-resolution policy. fda.gov/drugs/human-drug-compounding
The numbers behind this page
What we do not claim in this page
Every price quoted in this page comes from the programme's own pricing page and carries the date it was captured.
We do not claim these prices will hold. Compounded pricing moves within weeks, and a figure without a capture date is not a fact. We do not claim a compounded preparation is equivalent to an approved product: it is not FDA-approved, is not therapeutically equivalent to any brand-name product, and FDA does not review it for safety, effectiveness or manufacturing quality before marketing.
And we do not claim to be a clinical resource. Which molecule suits you, at what dose, and whether treatment is appropriate at all are questions for a prescribing clinician who has your history. This is price research, and it is only useful once those questions are settled.
Reading the price against the market
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
What the plan term is worth
The figures in this page sit inside a market with a measurable shape, and that shape is what makes any single price readable.
Several programmes publish two prices: the advertised rate, which requires a commitment, and the month-to-month rate, which does not. The gap between them is the price of flexibility, and it is rarely presented that way.
Compounded medication is generally not refundable once shipped, and most discontinuation happens in the first three months — precisely the window a twelve-month prepayment covers. Committing at signup and committing after reaching a dose you tolerate are materially different decisions, even though the advertised rate is identical.
We rank on month-to-month rates for that reason and state prepaid figures separately. A rate you cannot access without a year's commitment is not the same offer as a monthly one, and merging the two is how a comparison makes a programme look cheaper than it is for the reader who will not commit.
Questions this page answers
Are compounded GLP-1 medicines FDA-approved?
No. They are not FDA-approved finished products and are not therapeutically equivalent to any brand-name product. FDA does not review them for safety, effectiveness or manufacturing quality before marketing.
Why do the same programmes quote two different prices?
Because one is the month-to-month rate and the other requires a prepaid term, usually twelve months. We rank on the month-to-month figure and state the prepaid rate separately, since a rate requiring a year's commitment is not the same offer.
Where do these prices come from?
Each is read from the programme's own published pricing page and carries its capture date. The full set of 24 standard-dose records is at /api/prices.json with molecule and dose class on every record.
What is the cheapest verified GLP-1 programme?
NexLife at $119 a month for semaglutide and $139 for tirzepatide on its 12-month plan, both at standard therapeutic dosing and first-party verified September 4, 2026. Month-to-month, NexLife is $139 and $169; Oak Longevity ($133, flat, no membership) is the next-cheapest semaglutide programme.